34
Participants
Start Date
November 26, 2020
Primary Completion Date
May 17, 2022
Study Completion Date
December 31, 2022
AK101 IV
AK101 will be administered intravenously.
AK101 SC
AK101 will be administered subcutaneously.
Placebo
Placebo will be administered subcutaneously or intravenously.
AK101 IV/AK101 SC
AK101 will be administered as intravenous infusion at Week8, then subcutaneously every 8 weeks thereafter .
Peking Union Medical College Hospital, Beijing
Shengjing Hospital of China Medical University, Shengyang
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
Nanjing First Hospital, Nanjing
The Affiliated Hospital of Xuzhou Medical University, Xuzhou
The First Affiliated Hospital of Bengbu Medical College, Bengbu
Tianjing People's Hospital, Tianjing
The First Affiliated Hospital of Fujian Medical University, Fuzhou
People's Hospital of Wuhan University, Wuhan
Nanfang Hospital, Guangzhou
The Sixth Affiliated Hospital of Sun Yat-Sen University, Guanzhou
The Second Hospital of Hebei Medical University, Shijiazhuang
Lead Sponsor
Akeso
INDUSTRY